PL87112B1 - - Google Patents
Download PDFInfo
- Publication number
- PL87112B1 PL87112B1 PL1973162950A PL16295073A PL87112B1 PL 87112 B1 PL87112 B1 PL 87112B1 PL 1973162950 A PL1973162950 A PL 1973162950A PL 16295073 A PL16295073 A PL 16295073A PL 87112 B1 PL87112 B1 PL 87112B1
- Authority
- PL
- Poland
- Prior art keywords
- rna
- virus
- cells
- rifamycin
- dna
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 11
- 229930189077 Rifamycin Natural products 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960003292 rifamycin Drugs 0.000 claims description 6
- 238000005304 joining Methods 0.000 claims description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 14
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 13
- 102000004190 Enzymes Human genes 0.000 claims 13
- 108090000790 Enzymes Proteins 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 11
- 241000700159 Rattus Species 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 230000003612 virological effect Effects 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical compound OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 claims 8
- 241000282414 Homo sapiens Species 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 8
- -1 hydrazine compound Chemical class 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 7
- 241000699670 Mus sp. Species 0.000 claims 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 7
- 239000000047 product Substances 0.000 claims 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims 6
- 238000002474 experimental method Methods 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 239000001963 growth medium Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 210000004698 lymphocyte Anatomy 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 4
- 238000011534 incubation Methods 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 102100034343 Integrase Human genes 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 239000007983 Tris buffer Substances 0.000 claims 3
- 241001493065 dsRNA viruses Species 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000005623 Carcinogenesis Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 230000009471 action Effects 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 230000036952 cancer formation Effects 0.000 claims 2
- 231100000504 carcinogenesis Toxicity 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 238000004440 column chromatography Methods 0.000 claims 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- 230000035484 reaction time Effects 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- ZWPOAAKGAFHAEX-UHFFFAOYSA-N (2-hydrazinylidene-1,2-diphenylethylidene)hydrazine Chemical compound C=1C=CC=CC=1C(=NN)C(=NN)C1=CC=CC=C1 ZWPOAAKGAFHAEX-UHFFFAOYSA-N 0.000 claims 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 241000972773 Aulopiformes Species 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims 1
- 230000006820 DNA synthesis Effects 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 101000714168 Homo sapiens Testisin Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 claims 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 claims 1
- 239000004677 Nylon Substances 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 102100036494 Testisin Human genes 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 108091092356 cellular DNA Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000005757 colony formation Effects 0.000 claims 1
- 239000012531 culture fluid Substances 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000001085 differential centrifugation Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- LBOVMDOAMWYGHK-UHFFFAOYSA-N ethanol;methylsulfinylmethane Chemical compound CCO.CS(C)=O LBOVMDOAMWYGHK-UHFFFAOYSA-N 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 150000002429 hydrazines Chemical class 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000000670 limiting effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000464 low-speed centrifugation Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000037353 metabolic pathway Effects 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229920001778 nylon Polymers 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940080469 phosphocellulose Drugs 0.000 claims 1
- PVCOXMQIAVGPJN-UHFFFAOYSA-N piperazine-1,4-diamine Chemical compound NN1CCN(N)CC1 PVCOXMQIAVGPJN-UHFFFAOYSA-N 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 238000011533 pre-incubation Methods 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 1
- 229940081192 rifamycins Drugs 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 229940048086 sodium pyrophosphate Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 1
- 229940109171 rifamycin sv Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2507572 | 1972-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL87112B1 true PL87112B1 (US20100223739A1-20100909-C00005.png) | 1976-06-30 |
Family
ID=11215624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1973162950A PL87112B1 (US20100223739A1-20100909-C00005.png) | 1972-05-31 | 1973-05-30 |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1478563A (en) * | 1975-03-05 | 1977-07-06 | Lepetit Spa | Rifamycin derivatives |
-
1973
- 1973-03-29 GB GB1519173A patent/GB1392272A/en not_active Expired
- 1973-03-30 IE IE508/73A patent/IE37481B1/xx unknown
- 1973-04-02 IL IL41926A patent/IL41926A/en unknown
- 1973-04-03 ZA ZA732293A patent/ZA732293B/xx unknown
- 1973-05-08 AR AR247892A patent/AR198663A1/es active
- 1973-05-11 CA CA171,060A patent/CA992961A/en not_active Expired
- 1973-05-18 ES ES414894A patent/ES414894A1/es not_active Expired
- 1973-05-25 DE DE2326698A patent/DE2326698A1/de active Pending
- 1973-05-25 NL NL737307319A patent/NL154510B/xx not_active IP Right Cessation
- 1973-05-29 FR FR7319518A patent/FR2186231B1/fr not_active Expired
- 1973-05-29 SE SE7307611*A patent/SE386444B/xx unknown
- 1973-05-29 LU LU67695A patent/LU67695A1/xx unknown
- 1973-05-29 RO RO7374946A patent/RO65182A/ro unknown
- 1973-05-29 SU SU1920394A patent/SU514572A3/ru active
- 1973-05-29 JP JP48059434A patent/JPS516679B2/ja not_active Expired
- 1973-05-29 AT AT468173A patent/AT323885B/de not_active IP Right Cessation
- 1973-05-29 DD DD171159A patent/DD107285A5/xx unknown
- 1973-05-30 BE BE131720A patent/BE800276A/xx unknown
- 1973-05-30 HU HULE706A patent/HU167317B/hu unknown
- 1973-05-30 PL PL1973162950A patent/PL87112B1/pl unknown
- 1973-05-30 CH CH783173A patent/CH573433A5/xx not_active IP Right Cessation
- 1973-12-19 AR AR251497A patent/AR198715A1/es active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chiang et al. | Adenosylhomocysteine hydrolase inhibitors: synthesis of 5′-deoxy-5′-(isobutylthio)-3-deazaadenosine and its effect on Rous sarcoma virus and Gross murine leukemia virus | |
| EP0572437B1 (en) | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity | |
| Novinson et al. | 2-(Alkylthio)-1, 2, 4-triazolo [1, 5-a] pyrimidines as adenosine 3', 5'-monophosphate phosphodiesterase inhibitors with potential as new cardiovascular agents | |
| CN109134448B (zh) | 杂环化合物及其盐、制备方法、用途和药物 | |
| EP2694517A1 (en) | Protein kinase inhibitors | |
| EA029614B1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
| JP2000515550A (ja) | サイクリン依存キナーゼ２およびＩκＢ―αのプリン阻害剤 | |
| CN113683616A (zh) | Kras g12c突变蛋白抑制剂 | |
| CN112047950B (zh) | 咪唑并吡嗪类衍生物及其合成方法和应用 | |
| JP2002520415A (ja) | 癌の治療に有用な無水改変キャンサリジン類似体 | |
| US3865812A (en) | 3-Acylhydrazonomethyl rifamycins | |
| WO1993017021A1 (en) | Heterocyclic compounds for enhancing antitumor activity | |
| CA1131631A (en) | Quinazoline derivatives and pharmaceutical preparations | |
| PL87112B1 (US20100223739A1-20100909-C00005.png) | ||
| CA1162537A (en) | Imidazoquinazoline derivatives | |
| NO180194B (no) | 6-[X-(2-hydroksyetyl)aminoalkylÅ-5,11-diokso-5,6-dihydro-11-H-indeno[1,2-cÅisokinoliner og anvendelse derav til fremstilling av medikamenter, samt medikament inneholdende slike kinoliner | |
| US3862934A (en) | 3-Hydrazonomethyl rifamycins | |
| US3900465A (en) | 3-formylrifamycin azines | |
| US3817986A (en) | Pyrono-rifamycins | |
| US3829417A (en) | Imidazole substituted rifamycins | |
| CN114573548A (zh) | 一种硝呋齐特类杂环苄叉酰肼衍生物及其合成方法、用途 | |
| US3933800A (en) | New 3-formylrifamycin SV derivatives | |
| WO2005054203A1 (fr) | Derives de quinoline substitues par des groupes amino aliphatiques et preparation et utilisation pharmaceutique de ces derives | |
| CA2310398C (en) | 5h-pyrano[2,3-d:6,5-d']dipyrimidine derivatives having an antibacterial, antiviral and immuno-modulating activity | |
| US3847901A (en) | 3-alkenyl substituted rifamycin sv compounds |